paroxetine has been researched along with Genetic Predisposition in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cizmarikova, M; Dragasek, J; Kolarcik, P; Mojzis, J; Vancova, Z; Zofcakova, S | 1 |
| Kato, M; Kinoshita, T; Koshikawa, Y; Nonen, S; Ogata, H; Sunada, N; Takekita, Y; Wakeno, M | 1 |
| Akil, H; Clinton, SM; Cohen, JL; Fant, AD; Glover, ME; Jackson, NL; Pugh, PC | 1 |
| Haraguchi, K; Ieiri, I; Imuta, N; Kobayashi, D; Koyama, S; Mine, K; Murata, Y; Nishimura, R | 1 |
| Fukuo, Y; Inada, T; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Kushima, I; Matsunaga, S; Naitoh, H; Nakamura, J; Okochi, T; Ozaki, N; Umene-Nakano, W; Yoshimura, R | 1 |
| Li, L; Lin, M; Qian, MC; Shen, XH; Sun, JS; Yang, JH; Zhang, J; Zhong, H | 1 |
| Hokoishi, K; Iga, J; Kinouchi, S; Nakataki, M; Numata, S; Ohmori, T; Sano, A; Song, H; Tanabe, H; Tayoshi-Shibuya, S; Ueno, S; Yamauchi, K | 1 |
| Haraguchi, K; Hosoi, M; Ieiri, I; Iwata, N; Kinukawa, N; Kobayashi, D; Mine, K; Murakami, Y; Ohtani, H; Ozaki, N; Sawada, Y; Suzuki, T; Tanaka, M | 1 |
| Azuma, J; Fukuda, T; Hosoi, Y; Ikenaga, Y; Kato, M; Kinoshita, T; Mandelli, L; Okugawa, G; Serretti, A; Takekita, Y; Wakeno, M | 1 |
3 trial(s) available for paroxetine and Genetic Predisposition
| Article | Year |
|---|---|
[Effects of apolipoprotein E genetic polymorphism on susceptibility of depression and efficacy of antidepressants].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Apolipoproteins E; Cyclohexanols; Depression; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2012 |
Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Case-Control Studies; Depressive Disorder, Major; Female; Gene Expression Regulation; Genetic Predisposition to Disease; Humans; Leukocytes; Male; Middle Aged; Paroxetine; RNA, Messenger; Vascular Endothelial Growth Factor A | 2007 |
Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Female; Genetic Predisposition to Disease; Humans; Incidence; Japan; Male; Middle Aged; Nausea; Paroxetine; Polymorphism, Genetic; Receptors, Serotonin, 5-HT3; Risk Factors; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2008 |
6 other study(ies) available for paroxetine and Genetic Predisposition
| Article | Year |
|---|---|
Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily B; Depression; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Male; Paroxetine; Polymorphism, Single Nucleotide; Slovakia; Treatment Outcome | 2018 |
Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluvoxamine; Genetic Predisposition to Disease; Genotype; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Linkage Disequilibrium; Male; Middle Aged; Paroxetine; Polymorphism, Single Nucleotide | 2019 |
Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.
Topics: Amygdala; Animals; Animals, Newborn; Anxiety Disorders; Depressive Disorder; Disease Models, Animal; Exploratory Behavior; Female; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Hippocampus; Male; Maternal Behavior; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2015 |
Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cytochrome P-450 CYP2D6; Depressive Disorder; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Risk Factors; Serotonin Plasma Membrane Transport Proteins; Substance Withdrawal Syndrome | 2010 |
Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population.
Topics: Adult; Asian People; Case-Control Studies; Circadian Clocks; Depressive Disorder, Major; Endopeptidases; Female; Fluvoxamine; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Male; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Ubiquitin | 2011 |
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.
Topics: Adult; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Depressive Disorder, Major; Drug Resistance, Multiple; Female; Genes, MDR; Genetic Predisposition to Disease; Genetic Variation; Genotype; Haplotypes; Humans; Male; Middle Aged; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sex Factors; Treatment Outcome | 2008 |